Author: Nicholas Caito

Epidermal growth factor receptors containing a single tyrosine in their C-terminal tail bind different effector molecules and are signaling-competent.

Gill K., Macdonald-Obermann J.L., & Pike L.J. (2017). “Epidermal growth factor receptors containing a single tyrosine in their C-terminal tail bind different effector molecules and are signaling-competent.” J Biol Chem. 2017 Dec 15;292(50):20744-20755. doi: 10.1074/jbc.M117.802553. Epub 2017 Oct 26. (Abstract)

Combining short- and long-range fluorescence reporters with simulations to explore the intramolecular dynamics of an intrinsically disordered protein.

Zosel F., Haenni D., Soranno A., Nettels D., & Schuler B. (2017). “Combining short- and long-range fluorescence reporters with simulations to explore the intramolecular dynamics of an intrinsically disordered protein.” J Chem Phys. 2017 Oct 21;147(15):152708. doi: 10.1063/1.4992800. (Abstract)

24th Annual Biochemistry, Biophysics and Structural Biology (BBSB) Graduate Student Retreat

The Annual BBSB retreat was held on October 20th and 21st, 2017 at the Cedar Creek. This year the keynote speakers were: Drs. Andrea Soranno and Rui Zhang, Assistant Professors in the Department of Biochemistry and Molecular Biophysics. Dr. Soranno presented on “Single-molecule fluorescence spectroscopy of intrinsically disordered proteins”. Dr. Zhang presented on “What can you do with cryo-EM”. Friday evening concluded with a poster session. In addition to the two keynote speakers, various students presented talks on their research during the day on Friday and Saturday. (more…)

Multifunctional inhibitors of MET/RON signaling and cross-talk with EGFR/HER2

October 2nd, 2017 – Jim Janetka, PhD, Associate Professor of Biochemistry and Molecular Biophysics and Chemistry Adjunct received a two year, Career Catalyst Research (CCR) Competitive Renewal Grant Program award from Susan G. Komen for the Cure for his research entitled “Multifunctional inhibitors of MET/RON signaling and cross-talk with EGFR/HER2”. The work is focused on developing new drugs to treat breast cancer by dual targeting of the tumor and its microenvironment.